242 related articles for article (PubMed ID: 36072608)
1. Effect of Recent Exacerbation History on the Efficacy of Once-Daily Single-Inhaler Fluticasone Furoate/Umeclidinium/Vilanterol Triple Therapy in Patients with Chronic Obstructive Pulmonary Disease in the FULFIL Trial.
Panettieri RA; Camargo CA; Cheema T; El Bayadi SG; Fiel S; Vila TM; Jain RG; Midwinter D; Thomashow B; Ludwig-Sengpiel A; Lipson DA
Int J Chron Obstruct Pulmon Dis; 2022; 17():2043-2052. PubMed ID: 36072608
[TBL] [Abstract][Full Text] [Related]
2. Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI) Triple Therapy Compared with Other Therapies for the Treatment of COPD: A Network Meta-Analysis.
Ismaila AS; Haeussler K; Czira A; Youn JH; Malmenäs M; Risebrough NA; Agarwal J; Nassim M; Sharma R; Compton C; Vogelmeier CF; Han MK; Halpin DMG
Adv Ther; 2022 Sep; 39(9):3957-3978. PubMed ID: 35849317
[TBL] [Abstract][Full Text] [Related]
3. Single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol plus umeclidinium using two inhalers for chronic obstructive pulmonary disease: a randomized non-inferiority study.
Bremner PR; Birk R; Brealey N; Ismaila AS; Zhu CQ; Lipson DA
Respir Res; 2018 Jan; 19(1):19. PubMed ID: 29370819
[TBL] [Abstract][Full Text] [Related]
4. The Efficacy and Safety of Once-daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-daily Budesonide/Formoterol in a Subgroup of Patients from China with Symptomatic COPD at Risk of Exacerbations (FULFIL Trial).
Zheng J; Zhong N; Wang C; Huang Y; Chen P; Wang L; Hui F; Zhao L; Wang H; Luo L; Du X; Han Goh A; Lipson DA
COPD; 2018; 15(4):334-340. PubMed ID: 30265816
[TBL] [Abstract][Full Text] [Related]
5. The IMPACT Study - Single Inhaler Triple Therapy (FF/UMEC/VI) Versus FF/VI And UMEC/VI In Patients With COPD: Efficacy And Safety In A Japanese Population.
Kato M; Tomii K; Hashimoto K; Nezu Y; Ishii T; Jones CE; Kilbride S; Gross AS; Clifton CS; Lipson DA
Int J Chron Obstruct Pulmon Dis; 2019; 14():2849-2861. PubMed ID: 31839705
[TBL] [Abstract][Full Text] [Related]
6. Effect of Age on the Efficacy and Safety of Once-Daily Single-Inhaler Triple-Therapy Fluticasone Furoate/Umeclidinium/Vilanterol in Patients With COPD: A Post Hoc Analysis of the Informing the Pathway of COPD Treatment Trial.
Hanania NA; Mannino DM; Criner GJ; Dransfield MT; Han MK; Jones CE; Kilbride S; Lomas DA; Martin N; Martinez FJ; Singh D; Wise RA; Halpin DMG; Lima R; Lipson DA
Chest; 2021 Mar; 159(3):985-995. PubMed ID: 33031829
[TBL] [Abstract][Full Text] [Related]
7. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis.
Bardsley S; Criner GJ; Halpin DMG; Han MK; Hanania NA; Hill D; Lange P; Lipson DA; Martinez FJ; Midwinter D; Siler TM; Singh D; Wise RA; van Zyl-Smit RN; Berkman N
Respir Med; 2022 Dec; 205():107040. PubMed ID: 36470149
[TBL] [Abstract][Full Text] [Related]
8. Once-daily single-inhaler versus twice-daily multiple-inhaler triple therapy in patients with COPD: lung function and health status results from two replicate randomized controlled trials.
Ferguson GT; Brown N; Compton C; Corbridge TC; Dorais K; Fogarty C; Harvey C; Kaisermann MC; Lipson DA; Martin N; Sciurba F; Stiegler M; Zhu CQ; Bernstein D
Respir Res; 2020 May; 21(1):131. PubMed ID: 32471423
[TBL] [Abstract][Full Text] [Related]
9. 24-Hour Serial Spirometric Assessment of Once-Daily Fluticasone Furoate/Umeclidinium/Vilanterol Versus Twice-Daily Budesonide/Formoterol in Patients with COPD: Analysis of the FULFIL Study.
Lipson DA; Birk R; Brealey N; Zhu CQ
Adv Ther; 2020 Dec; 37(12):4894-4909. PubMed ID: 33011864
[TBL] [Abstract][Full Text] [Related]
10. Once-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life.
Tabberer M; Lomas DA; Birk R; Brealey N; Zhu CQ; Pascoe S; Locantore N; Lipson DA
Adv Ther; 2018 Jan; 35(1):56-71. PubMed ID: 29313286
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of once-daily single-inhaler triple therapy (FF/UMEC/VI) versus FF/VI in patients with inadequately controlled asthma (CAPTAIN): a double-blind, randomised, phase 3A trial.
Lee LA; Bailes Z; Barnes N; Boulet LP; Edwards D; Fowler A; Hanania NA; Kerstjens HAM; Kerwin E; Nathan R; Oppenheimer J; Papi A; Pascoe S; Brusselle G; Peachey G; Sule N; Tabberer M; Pavord ID
Lancet Respir Med; 2021 Jan; 9(1):69-84. PubMed ID: 32918892
[TBL] [Abstract][Full Text] [Related]
12. Outcomes of Patients with COPD Treated with ICS/LABA Before and After Initiation of Single-Inhaler Triple Therapy with Fluticasone Furoate/Umeclidinium/Vilanterol (FF/UMEC/VI).
McCormack M; Paczkowski R; Gronroos NN; Noorduyn SG; Lee L; Veeranki P; Johnson MG; Igboekwe E; Kahle-Wrobleski K; Panettieri R
Adv Ther; 2024 Mar; 41(3):1245-1261. PubMed ID: 38310193
[TBL] [Abstract][Full Text] [Related]
13. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol and umeclidinium/vilanterol in patients with COPD: results on cardiovascular safety from the IMPACT trial.
Day NC; Kumar S; Criner G; Dransfield M; Halpin DMG; Han MK; Jones CE; Kaisermann MC; Kilbride S; Lange P; Lomas DA; Martin N; Martinez FJ; Singh D; Wise R; Lipson DA
Respir Res; 2020 Jun; 21(1):139. PubMed ID: 32503599
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study.
Nakamura Y; Hozawa S; Sagara H; Ohbayashi H; Lee LA; Crawford J; Tamaoki J; Nishi T; Fowler A
Curr Med Res Opin; 2021 Sep; 37(9):1657-1665. PubMed ID: 34162298
[TBL] [Abstract][Full Text] [Related]
15. Single inhaler triple therapy (FF/UMEC/VI) versus FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the China cohort in the IMPACT trial.
Zheng J; Zhong N; Wang C; Wei LP; Zhou XD; Zhao L; Dong Yuan Y; He B; Wu B; Du X; Song J; Lipson DA
Curr Med Res Opin; 2021 Jan; 37(1):145-155. PubMed ID: 33124900
[TBL] [Abstract][Full Text] [Related]
16. The effect of exacerbation history on outcomes in the IMPACT trial.
Halpin DMG; Dransfield MT; Han MK; Jones CE; Kilbride S; Lange P; Lipson DA; Lomas DA; Martinez FJ; Pascoe S; Singh D; Wise R; Criner GJ
Eur Respir J; 2020 May; 55(5):. PubMed ID: 32299860
[TBL] [Abstract][Full Text] [Related]
17. Once-daily fluticasone furoate/vilanterol 100/25 mcg versus twice daily combination therapies in COPD - mixed treatment comparisons of clinical efficacy.
Stynes G; Svedsater H; Wex J; Lettis S; Leather D; Castelnuovo E; Detry M; Berry S
Respir Res; 2015 Feb; 16(1):25. PubMed ID: 25849223
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective.
Schroeder M; Benjamin N; Atienza L; Biswas C; Martin A; Whalen JD; Izquierdo Alonso JL; Riesco Miranda JA; Soler-Cataluña JJ; Huerta A; Ismaila AS
Int J Chron Obstruct Pulmon Dis; 2020; 15():1621-1632. PubMed ID: 32764908
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of FF/UMEC/VI compared with FF/VI and UMEC/VI in patients with COPD: subgroup analysis of the Spain cohort in IMPACT.
Marín JM; Mateos L; Roldán J; Echave-Sustaeta JM; Pascual-Guardia S; Pardo MV; Velasco B; Jones CE; Kilbride S; Lipson DA
Ther Adv Respir Dis; 2020; 14():1753466620963021. PubMed ID: 33121372
[TBL] [Abstract][Full Text] [Related]
20. InforMing the PAthway of COPD Treatment (IMPACT Trial) Single-Inhaler Triple Therapy (Fluticasone Furoate/Umeclidinium/Vilanterol) Versus Fluticasone Furoate/Vilanterol and Umeclidinium/Vilanterol in Patients With COPD: Analysis of the Western Europe and North America Regions.
Bourdin A; Criner G; Devouassoux G; Dransfield M; Halpin DMG; Han MK; Jones CE; Kalhan R; Lange P; Lettis S; Lipson DA; Lomas DA; Echave-Sustaeta María-Tomé JM; Martin N; Martinez FJ; Quasny H; Sail L; Siler TM; Singh D; Thomashow B; Watz H; Wise R; Hanania NA
Chronic Obstr Pulm Dis; 2021 Jan; 8(1):76-90. PubMed ID: 33156982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
